[
  {
    "ts": null,
    "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
    "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
    "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757545741,
      "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
      "id": 136692857,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153211726/image_2153211726.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
      "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th",
    "url": "https://finnhub.io/api/news?id=5441a6b9bccc28372b6308d91480d5ae3eaed961dd66d790b0b9d6fe1774b1a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757537538,
      "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
      "id": 136688951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th",
      "url": "https://finnhub.io/api/news?id=5441a6b9bccc28372b6308d91480d5ae3eaed961dd66d790b0b9d6fe1774b1a9"
    }
  },
  {
    "ts": null,
    "headline": "US pharma giant Merck ditches plan for $1.4-bn research centre in UK",
    "summary": "Merck, the US pharmaceutical group, said on Wednesday it has dropped plans to build a $1.4-billion research centre in Britain, blaming the country's \"lack of investment\" in the sector and its drugs prices.Merck's decision follows that of UK sectoral rival AstraZeneca to abandon plans to build a $540-million vaccine factory in Britain, in the Liverpool region, because of what it said were insufficient state incentives.",
    "url": "https://finnhub.io/api/news?id=2361911ece04781a6524eda768cf6ead0c35d57022cb12ff2dddf6fd204d96db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757535083,
      "headline": "US pharma giant Merck ditches plan for $1.4-bn research centre in UK",
      "id": 136688952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck, the US pharmaceutical group, said on Wednesday it has dropped plans to build a $1.4-billion research centre in Britain, blaming the country's \"lack of investment\" in the sector and its drugs prices.Merck's decision follows that of UK sectoral rival AstraZeneca to abandon plans to build a $540-million vaccine factory in Britain, in the Liverpool region, because of what it said were insufficient state incentives.",
      "url": "https://finnhub.io/api/news?id=2361911ece04781a6524eda768cf6ead0c35d57022cb12ff2dddf6fd204d96db"
    }
  },
  {
    "ts": null,
    "headline": "US drugmaker scraps plans for £1bn UK research centre",
    "summary": "One of America’s largest drug companies has ditched plans to open a £1bn research centre in London amid a growing row with the Government over surging NHS charges.",
    "url": "https://finnhub.io/api/news?id=c2c49d77a5bf73bdf67e9f83ea5701576a5f104af422b239f6140214e571d2ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757532786,
      "headline": "US drugmaker scraps plans for £1bn UK research centre",
      "id": 136688953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "One of America’s largest drug companies has ditched plans to open a £1bn research centre in London amid a growing row with the Government over surging NHS charges.",
      "url": "https://finnhub.io/api/news?id=c2c49d77a5bf73bdf67e9f83ea5701576a5f104af422b239f6140214e571d2ab"
    }
  },
  {
    "ts": null,
    "headline": "Merck to scrap London drug research centre",
    "summary": "The U.S. drugmaker no longer plans to occupy the Belgrove House site at King's Cross, which was due to open in 2027.  Pharmaceutical companies have been shoring up investments in the U.S. amid the Trump administration's tariff threats and pressure to move more manufacturing to the U.S.  Merck said its decision \"reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments.\"",
    "url": "https://finnhub.io/api/news?id=029320076fd97e99fafd8d6a1bb5dab8477527a675707744539a1e995a800c16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757524477,
      "headline": "Merck to scrap London drug research centre",
      "id": 136688954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The U.S. drugmaker no longer plans to occupy the Belgrove House site at King's Cross, which was due to open in 2027.  Pharmaceutical companies have been shoring up investments in the U.S. amid the Trump administration's tariff threats and pressure to move more manufacturing to the U.S.  Merck said its decision \"reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments.\"",
      "url": "https://finnhub.io/api/news?id=029320076fd97e99fafd8d6a1bb5dab8477527a675707744539a1e995a800c16"
    }
  },
  {
    "ts": null,
    "headline": "Merck manager’s awkward whispers didn’t constitute harassment, judge rules",
    "summary": "The plaintiff, who spoke with a “heavy African accent,” said a manager’s comment that his voice is “very specific” was discriminatory.",
    "url": "https://finnhub.io/api/news?id=1dea187adb0b8d3a8983c75dedbdf81d482c7093ee9bb51d041698f98940990a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757524020,
      "headline": "Merck manager’s awkward whispers didn’t constitute harassment, judge rules",
      "id": 136688955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The plaintiff, who spoke with a “heavy African accent,” said a manager’s comment that his voice is “very specific” was discriminatory.",
      "url": "https://finnhub.io/api/news?id=1dea187adb0b8d3a8983c75dedbdf81d482c7093ee9bb51d041698f98940990a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
    "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
    "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520120,
      "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
      "id": 136688660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
      "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a"
    }
  },
  {
    "ts": null,
    "headline": "Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership",
    "summary": "Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.",
    "url": "https://finnhub.io/api/news?id=33be676d416451db2dc19eb1bb13dc839db67235f49e989e18f331ae23aea73a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757507580,
      "headline": "Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership",
      "id": 136688957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.",
      "url": "https://finnhub.io/api/news?id=33be676d416451db2dc19eb1bb13dc839db67235f49e989e18f331ae23aea73a"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm",
    "summary": "Discover why Novo Nordisk A/Sâs 2025 restructuring and staff cuts shouldn't deter investors. Click to explore the long-term NVO growth potential and outlook.",
    "url": "https://finnhub.io/api/news?id=c2eac514284ad95a72c7729649667ef81b0c884a2bcb6e87d90cf5eded8ad837",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757506466,
      "headline": "Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm",
      "id": 136685040,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk A/Sâs 2025 restructuring and staff cuts shouldn't deter investors. Click to explore the long-term NVO growth potential and outlook.",
      "url": "https://finnhub.io/api/news?id=c2eac514284ad95a72c7729649667ef81b0c884a2bcb6e87d90cf5eded8ad837"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating",
    "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Bradley Canino from Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and a $40 price target. The analyst noted that they liked the stock when it was […]",
    "url": "https://finnhub.io/api/news?id=4d03a4744df24c218664c9e5948dfa1f3882e0d48ebdd470cd01c3c9e34986a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757483979,
      "headline": "Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating",
      "id": 136688958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Bradley Canino from Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and a $40 price target. The analyst noted that they liked the stock when it was […]",
      "url": "https://finnhub.io/api/news?id=4d03a4744df24c218664c9e5948dfa1f3882e0d48ebdd470cd01c3c9e34986a2"
    }
  }
]